Is ganirelix FDA-approved, and what does the research show?

What is ganirelix?

Ganirelix is a man-made peptide of ten amino acids that blocks the receptor for gonadotropin-releasing hormone, GnRH ¹. GnRH is a signal from the brain to the pituitary, a gland at the base of the brain. The label says its pulses make the pituitary release two hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ¹. In a natural cycle, a large mid-cycle release of GnRH sets off an LH surge, and that surge triggers ovulation, the release of the egg ¹.

With six of its amino acids changed, ganirelix has "high antagonistic activity" against GnRH, the label says ⁴. Its only approved use is in fertility treatment, and it is not a wellness, weight or performance peptide ¹.

Is ganirelix FDA-approved?

Yes. Ganirelix is approved by FDA as a prescription medicine ², ¹. FDA's Drugs@FDA record, its public register of approved drugs, shows Organon's new drug application, NDA 021057, approved on July 29, 1999, with marketing status "Prescription" ². The approval letter names the product Antagon ³. The current label calls it Ganirelix Acetate Injection, which Organon still sells ⁴, ⁷.

The label approves it "for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation" ⁴, ⁵. Controlled ovarian hyperstimulation is the phase of in vitro fertilization, IVF, in which a woman takes FSH injections so that several eggs mature at once ¹. A premature LH surge during that phase would set off ovulation before the eggs can be retrieved, and ganirelix is given to prevent it ¹.

That is the label's only indication. It lists no use in men and none for weight, muscle, testosterone or aging, and the clinical studies enrolled women undergoing IVF ¹. The label says the drug "should be prescribed by physicians who are experienced in infertility treatment" ⁴. Drugs@FDA also lists seven generic applications for ganirelix acetate, six with marketing status "Prescription" and one discontinued, as of November 9, 2026, the date of its data ². One of the six, ANDA 204246 from Sun Pharma, carries the brand name Fyremadel ².

See the FDA status of every peptide, updated weekly.

How does ganirelix work?

Ganirelix "acts by competitively blocking the GnRH receptors on the pituitary gonadotroph," the cells that make LH and FSH ⁴. The block is rapid and reversible ¹. It suppresses LH more than FSH, and the label says LH and FSH "are fully recovered within 48 hours" after the drug is stopped ⁴.

An antagonist works differently from a GnRH agonist, a drug that switches the receptor on, the class that includes leuprolide, a different molecule with its own page. The leuprolide label says daily doses cause "an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH)," and that LH and FSH fall only with continuous use ⁸. With ganirelix, the label reports that "an initial release of endogenous gonadotropins has not been detected," which it calls "consistent with an antagonist effect" ⁴. So the antagonist blocks the receptor at once, where the agonist first stimulates it and shuts it down only later ¹, ⁸. In the North American trial below, the ganirelix course was shorter, with fewer injections ⁶.

What does the research show?

FDA approved ganirelix on two randomized trials, which the label describes, so its evidence level is "Approved for a use" ¹. Both enrolled women with normal hormone levels and a normal pelvic ultrasound ¹. Both were meant to exclude women with polycystic ovary syndrome, a hormonal disorder of the ovaries, or a low egg reserve ¹. Each woman had one treatment cycle, with FSH injections from day 2 or 3 of her cycle and ganirelix from the sixth day of FSH ¹. An injection of hCG, human chorionic gonadotropin, then matured the eggs before retrieval ¹.

Studied in people at six dose levels: a multicenter, randomized dose-finding study, double-blind, meaning neither patients nor doctors knew the dose, gave ganirelix to 332 women undergoing stimulation for IVF ¹. The level of LH on the day of hCG fell as the dose rose ¹. The dose later approved had the highest pregnancy and implantation rates ¹. In that arm of 70 women, 25 (35.7 percent) had a pregnancy seen on ultrasound at five to six weeks after embryo transfer ¹. One of the 70 had an LH rise above the study's threshold ¹.

Studied in people against a GnRH agonist: a multicenter, randomized study, open-label, meaning patients and doctors knew the treatment, treated 463 women with ganirelix ¹. The reference treatment was a GnRH agonist given from the luteal phase, the second half of the previous cycle ¹.

In the ganirelix arm, 440 women reached egg retrieval, with a mean of 8.7 eggs, and 399 had an embryo transfer ¹. An ongoing pregnancy at 12 to 16 weeks after embryo transfer was recorded in 94 of the 463 women (20.3 percent) ¹. A premature LH surge before hCG occurred in less than 1 percent of the 463 ¹. The label gives no figures for the agonist arm ¹.

Studied in North America against leuprolide: a phase 3 trial, the last stage of testing, multicenter and open-label, ran at IVF centers ⁶. It randomized 313 women in couples with reduced fertility to one cycle of ganirelix or of leuprolide on its longer standard schedule, each with follitropin beta, a man-made FSH ⁶. The ganirelix group had a mean of 11.6 eggs retrieved per attempt against 14.1 on leuprolide ⁶.

Fertilization rates were 62.4 and 61.9 percent, and implantation rates 21.1 and 26.1 percent ⁶. Clinical pregnancy per attempt was 35.4 percent on ganirelix and 38.4 percent on leuprolide, and ongoing pregnancy 30.8 against 36.4 percent ⁶. The authors concluded that ganirelix "has a shorter duration and fewer injections but produces a similar pregnancy rate" ⁶.

ClinicalTrials.gov, the U.S. registry of clinical trials, listed 105 studies with ganirelix as an intervention on November 10, 2026, nearly all in infertility, IVF and related reproductive conditions ⁹. A few use it to switch off the pituitary in studies of menopause, puberty, sleep, blood vessels, sodium balance and blood pressure on standing ⁹. None studies it for weight, muscle or athletic performance ⁹. Outside fertility care, studies give ganirelix only as a research tool to switch off sex hormones, in women and in men ⁹.

What are the side effects?

The label's safety data come from two randomized, multicenter controlled studies, with 794 women treated for 1 to 14 days ¹. Events were counted from the first dose to the pregnancy ultrasound, "without regard to causality" ⁴. The most common were abdominal pain of gynecological origin, in 4.8 percent, fetal death, in 3.7 percent, and headache, in 3.0 percent ¹. Ovarian hyperstimulation syndrome was recorded in 2.4 percent and vaginal bleeding in 1.8 percent ¹. Injection-site reactions, nausea and gastrointestinal abdominal pain were each recorded in about 1 percent ¹.

Ovarian hyperstimulation syndrome, OHSS, is a complication of the stimulation phase, and the label tells clinicians to withhold hCG when the ovaries are abnormally enlarged ¹. In the North American trial, moderate injection-site reactions were reported by 11.9 percent on ganirelix against 24.4 percent on leuprolide, and severe reactions by 0.6 against 1.1 percent ⁶. After marketing, "rare cases of hypersensitivity reactions, including anaphylaxis (including anaphylactic shock), angioedema and urticaria have been reported," that is, severe allergic reactions, swelling beneath the skin and hives, some "as early as with the first dose" ⁴.

An observational study of more than 1,000 newborns found the rate of congenital anomalies, birth defects, after ganirelix cycles "comparable with" that reported after GnRH agonist cycles, using historical controls ⁴. The label calls the causal relationship "unknown" ⁴. In 11.9 percent of women in the trials, the count of neutrophils, a type of white blood cell, was 8.3 x 10^9/L or higher ⁴. The label says the "clinical significance" of that "was not determined" ⁴.

The label contraindicates ganirelix, that is, says it must not be given, in "known or suspected pregnancy" ⁴. It also contraindicates it in "known hypersensitivity to GnRH or any other GnRH analog" ⁴. The third is known hypersensitivity to ganirelix acetate "or to any of its components" ⁴. Its warnings say "pregnancy must be excluded" before treatment and that safe use in pregnancy "has not been established" ⁴.

In pregnant rats and rabbits it increased litter resorption, the loss of embryos in the womb, which the label says "could result in fetal loss in humans" ⁴. It "should not be used by lactating women" and is "not advised in women with severe allergic conditions" ⁴.

In sport

Ganirelix is not named on WADA's 2026 Prohibited List ¹⁰. WADA, the World Anti-Doping Agency, does list the opposite class: section S2.2.1, "Testosterone-stimulating peptides in males," names "gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues," with leuprorelin, the international name for leuprolide, among its examples ¹⁰, ¹¹. Section S4, "Hormone and metabolic modulators," notes that some of its substances are found in medicines for "infertility (female)," but it names no GnRH antagonist ¹⁰.

What JumpstartMD offers

JumpstartMD does not prescribe ganirelix. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.